•  
  •  
  •  
  •  

2026-05-21 06:30:44

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • GRSE Launches Next-Gen OPV: Crafted for Vigilance, Built for Victory
  • Muthoot Finance Ranked India's No. 1 Most Trusted Financial Services Brand for 10th Consecutive Year
  • Ampere Magnus G Max by Greaves Electric Mobility Wins 'Family Scooter of the Year' at Times Drive Auto Summit and Awards 2026
  • Eris delivers 11% yoy growth in Domestic Formulations with 37% EBIDTA margin in FY26
  • DevX - Standalone Revenue from Operations grew 34.3% YoY in FY26

Keywords Selected:  Launch

Research

  • Company Update - Atul Auto - ICICI Direct
  • KPMG in India Report - 5G driving the next growth wave for Digital India
  • Natco Pharma - Natco and Teva launch Revlimid in the US - ICICI Securities

Stock Report

  • Comfort Fincap Ltd launches Consumer Durable Loan
  • Force Motors launches New Force Traveller N Range - Reimagined for the future of shared passenger mobility
  • ASMS and Huwel to Launch Cubo, India's Revolutionary Point-ofCare Molecular Diagnostics Platform Built for the World
  • Greaves Electric Mobility strengthens Ampere Magnus portfolio with the New Magnus Neo
  • Prithvi Exchange secures in-principle approval from Visa for Forex Card Launch
  • Apis India Limited's Misk launches Masala Dates - Seedless, Superfood-On-The-Go in Bold Indian Flavours
  • Glenmark Pharmaceuticals Inc., USA to launch Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials
  • Zydus plans to launch innovative Semaglutide Injection in India on Day 1 of patent expiry
  • Cosmo First to showcase multiple new product launches across businesses at PLASTINDIA 2026
  • Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial
  • Coforge Unveils 'Data Cosmos' - A Next-Gen AI-Enabled, CloudNative Data & Analytics Platform
  • Senores Pharmaceuticals, Inc. announces the approval and launch of Deferiprone Tablets USP, 500 mg & 1000 mg
  • Zydus launches biosimilar Denosumab 120 mg SC - protecting bone health in cancer patients
  • Bansal Wire Industries Ltd launches new product
  • Escorts Kubota Limited Introduces Third-Generation Ride-On Rice Transplanters in India
  • Marathon Nextgen Realty Launches ₹600 Crore Residential Development in Panvel
  • Glenmark Pharmaceuticals Inc., USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial
  • Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP
  • Nakoda Group of Industries Ltd diversifies into Beverages with Launch of NO CTRL - A New Brand of Energy and Flavoured Soft Drinks
  • EPACK Durable Ltd introduces Vacuum Cleaner
  • United Breweries Relaunches Kalyani Black Label Strong in West Bengal
  • Royal Orchid Hotels Announces the Soft Launch of Iconiqa
  • Lehar Footwears launches athleisure brand Rannr
  • Nazara to publish hit PC Game Bodycam in Fortnite

Industry News

  • Allied Blenders and Distillers Limited brings its Zoya Special Batch Premium Gin to Maharashtra
  • Niva Bupa Health Insurance Introduces 'Aspire', a product for Young India
  • Honeywell Launches World's First 100% Hydrogen-Capable Gas Meter
  • Aviva India Launches Aviva Signature Guaranteed Income Plan

Latest Post

  • GRSE Launches Next-Gen OPV: Crafted for Vigilance, Built for Victory
  • Muthoot Finance Ranked India's No. 1 Most Trusted Financial Services Brand for 10th Consecutive Year
  • Ampere Magnus G Max by Greaves Electric Mobility Wins 'Family Scooter of the Year' at Times Drive Auto Summit and Awards 2026
  • Eris delivers 11% yoy growth in Domestic Formulations with 37% EBIDTA margin in FY26
  • DevX - Standalone Revenue from Operations grew 34.3% YoY in FY26


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025